SCHEMBL3206508

SCHEMBL3206508

Cc1ccc(NC(=O)Nc2sc(C(C)(C)C)cc2C(=O)N2CCNC(=O)C2(C)C)cc1C#CCN1CCOCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 18/20 0.46
MAPK13 O15264 2/20 0.37
RPS6KB1 P23443 2/20 0.37
MAPK12 P53778 1/20 0.37
MAPK11 Q15759 1/20 0.37
PLK4 O00444 1/20 0.36
AURKA O14965 1/20 0.36
DYRK3 O43781 1/20 0.36
JAK2 O60674 1/20 0.36
ROCK2 O75116 1/20 0.36
RPS6KA5 O75582 1/20 0.36
MAP4K4 O95819 1/20 0.36
ABL1 P00519 1/20 0.36
NTRK1 P04629 1/20 0.36
INSR P06213 1/20 0.36
LCK P06239 1/20 0.36
CSF1R P07333 1/20 0.36
LYN P07948 1/20 0.36
MET P08581 1/20 0.36
KIT P10721 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3208358 0.93 MAPK14 (0.46) MAPK14MAPK13RPS6KB1MAPK12MAPK11
SCHEMBL3218555 0.90 MAPK14 (0.42) MAPK14MAPK13RPS6KB1MAPK12MAPK11
SCHEMBL3206381 0.88 MAPK14 (0.44) MAPK14MAPK13RPS6KB1MAPK12MAPK11
SCHEMBL13488025 0.87 MAPK14 (0.50) MAPK14MAPK13MAPK12MAPK11
SCHEMBL3222820 0.87 MAPK14 (0.49) MAPK14MAPK13RPS6KB1MAPK12MAPK11
SCHEMBL3217468 0.85 MAPK14 (0.52) MAPK14MAPK13RPS6KB1MAPK12MAPK11
SCHEMBL3198252 0.85 MAPK14 (0.52) MAPK14MAPK13RPS6KB1MAPK12MAPK11
SCHEMBL3211761 0.85 MAPK14 (0.45) MAPK14RPS6KB1
SCHEMBL13487966 0.83 MAPK14 (0.45) MAPK14MAPK13RPS6KB1MAPK12MAPK11
SCHEMBL3219338 0.82 MAPK14 (0.50) MAPK14MAPK13RPS6KB1MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010019930-A1 UREA DERIVATIVES AS INHIBITORS OF MAP KINASES LOCUS PHARMACEUTICALS, INC. (US) 2010-02-18 WO disclosed
US-20100041642-A1 UREA INHIBITORS OF MAP KINASES LOCUS PHARMACEUTICALS, INC. (US) 2010-02-18 US disclosed
US-20100041642-A1 UREA INHIBITORS OF MAP KINASES LOCUS PHARMACEUTICALS, INC. (US) 2010-02-18 US disclosed
US-20100041642-A1 UREA INHIBITORS OF MAP KINASES LOCUS PHARMACEUTICALS, INC. (US) 2010-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041642-A1 UREA INHIBITORS OF MAP KINASES MAP4K2, MAP3K1, MAP3K20 MAPK14 33/4885MAPK13 44/4885RPS6KB1 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.